BACKGROUND: Results from preclinical studies have suggested that the organosulfur compound anethole dithiolethione (ADT) may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia. METHODS:One hundred twelve current and former smokers with a smoking history of at least 30 pack-years and at least one site of bronchial dysplasia identified by an autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive placebo or ADT at 25 mg orally thrice daily for 6 months. Each subject then underwent a follow-up bronchoscopy-directed biopsy. We used changes in histopathologic grade and nuclear morphometry index (MI) as the primary and secondary end point biomarkers, respectively. Chi-square tests with continuity correction were used to compare response rates on a lesion- and person-specific basis between the two study groups. All statistical tests were two-sided. RESULTS:One hundred one subjects had a follow-up bronchoscopy. In the lesion-specific analysis, progression rate of pre-existing dysplastic lesions by two or more grades and/or the appearance of new lesions was statistically significantly lower in the ADT group (8%) than in the placebo group (17%) (P<.001; difference = 9%, 95% confidence interval [CI] = 4% to 15%). In the person-specific analysis, the disease progression rate was statistically significantly lower in the ADT group (32%) than in the placebo group (59%) (P =.013; difference = 27%, 95% CI = 6% to 48%). The two treatment groups did not differ statistically significantly in terms of nuclear MI. Among individuals with an abnormal nuclear MI before treatment (29 in the ADT group and 25 in the placebo group), the progression rate in the ADT group (41%) was substantially lower than that in the placebo group (60%), although the difference was not statistically significant (P =.28; difference = 19%, 95% CI = -11% to 49%). Adverse events were mostly minor gastrointestinal symptoms that resolved with dose reduction or discontinuation of the medication. CONCLUSION: Our results suggest that, in smokers, ADT is a potentially efficacious chemoprevention agent for lung cancer.
RCT Entities:
BACKGROUND: Results from preclinical studies have suggested that the organosulfur compoundanethole dithiolethione (ADT) may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia. METHODS: One hundred twelve current and former smokers with a smoking history of at least 30 pack-years and at least one site of bronchial dysplasia identified by an autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive placebo or ADT at 25 mg orally thrice daily for 6 months. Each subject then underwent a follow-up bronchoscopy-directed biopsy. We used changes in histopathologic grade and nuclear morphometry index (MI) as the primary and secondary end point biomarkers, respectively. Chi-square tests with continuity correction were used to compare response rates on a lesion- and person-specific basis between the two study groups. All statistical tests were two-sided. RESULTS: One hundred one subjects had a follow-up bronchoscopy. In the lesion-specific analysis, progression rate of pre-existing dysplastic lesions by two or more grades and/or the appearance of new lesions was statistically significantly lower in the ADT group (8%) than in the placebo group (17%) (P<.001; difference = 9%, 95% confidence interval [CI] = 4% to 15%). In the person-specific analysis, the disease progression rate was statistically significantly lower in the ADT group (32%) than in the placebo group (59%) (P =.013; difference = 27%, 95% CI = 6% to 48%). The two treatment groups did not differ statistically significantly in terms of nuclear MI. Among individuals with an abnormal nuclear MI before treatment (29 in the ADT group and 25 in the placebo group), the progression rate in the ADT group (41%) was substantially lower than that in the placebo group (60%), although the difference was not statistically significant (P =.28; difference = 19%, 95% CI = -11% to 49%). Adverse events were mostly minor gastrointestinal symptoms that resolved with dose reduction or discontinuation of the medication. CONCLUSION: Our results suggest that, in smokers, ADT is a potentially efficacious chemoprevention agent for lung cancer.
Authors: Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller Journal: Cancer Prev Res (Phila) Date: 2011-06
Authors: Dorothy K Hatsukami; Neal L Benowitz; Stephen I Rennard; Cheryl Oncken; Stephen S Hecht Journal: Nicotine Tob Res Date: 2006-08 Impact factor: 4.244
Authors: Stephen Lam; Beau Standish; Corisande Baldwin; Annette McWilliams; Jean leRiche; Adi Gazdar; Alex I Vitkin; Victor Yang; Norihiko Ikeda; Calum MacAulay Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Ryan Holland; Mettachit Navamal; Murugesan Velayutham; Jay L Zweier; Thomas W Kensler; James C Fishbein Journal: Chem Res Toxicol Date: 2009-08 Impact factor: 3.739
Authors: Eric Edell; Stephen Lam; Harvey Pass; York E Miller; Thomas Sutedja; Timothy Kennedy; Gregory Loewen; Robert L Keith; Adi Gazdar Journal: J Thorac Oncol Date: 2009-01 Impact factor: 15.609
Authors: Stephen Lam; Sumithra J Mandrekar; Yaron Gesthalter; Katie L Allen Ziegler; Drew K Seisler; David E Midthun; Jenny T Mao; Marie Christine Aubry; Annette McWilliams; Don D Sin; Tawimas Shaipanich; Gang Liu; Evan Johnson; Andrea Bild; Marc E Lenburg; Diana N Ionescu; John Mayo; Joanne Eunhee Yi; Henry Tazelaar; William S Harmsen; Judith Smith; Avrum E Spira; Jennifer Beane; Paul J Limburg; Eva Szabo Journal: Cancer Prev Res (Phila) Date: 2016-09-22